共 33 条
- [1] Atassi M.Z., Basic immunological aspects of botulinum toxin therapy, Mov Disord, 19, SUPPL. 8, pp. 68-84, (2004)
- [2] Bentivoglio A.R., Fasano A., Ialongo T., Et al., Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs, Neurotox Res, 15, pp. 224-231, (2009)
- [3] Borodic G., Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides, Ophthal Plast Reconstr Surg, 22, pp. 239-240, (2006)
- [4] Brin M.F., Comella C.L., Jankovic J., Et al., Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay, Mov Disord, 23, pp. 1353-1360, (2008)
- [5] Ceballos-Baumann A.O., Dystonien, Bewegungsstörungen in der Neurologie, (1996)
- [6] Chinnapongse R., Lew M.F., Pagan F., Et al., A 7-year open-label safety and immunogenicity study of Myobloc in patients with cerviacal dystonia, Neurology, 74, pp. 86-87, (2010)
- [7] Dressler D., Complete secondary botulinum toxin therapy failure in blepharospasm, J Neurol, 247, pp. 809-810, (2000)
- [8] Dressler D., Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy, Eur Neurol, 48, pp. 26-29, (2002)
- [9] Dressler D., New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm, J Neurol, 251, (2004)
- [10] Dressler D., Bigalke H., Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure, J Neurol, 252, pp. 904-907, (2005)